Robert Young Kim
CIK 1971608 · View on SEC EDGAR ↗
First SEC filing: Feb. 7, 2024 · Latest: Feb. 7, 2024
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 5, 2024 | FDMT | S 10b5-1 | 552 | $30.05 | $16,588 | 1,043 Direct | -34.61% | Disposed | -48.3% (price as of 2026-08-19) |
| Feb. 5, 2024 | FDMT | S 10b5-1 | 6,000 | $30.05 | $180,300 | 1,595 Direct | -79.00% | Disposed | -48.3% (price as of 2026-08-19) |
| Feb. 5, 2024 | FDMT | S 10b5-1 | 6,000 | $30.05 | $180,300 | 1,595 Direct | -79.00% | Disposed | -48.3% (price as of 2026-08-19) |
| Feb. 5, 2024 | FDMT | S 10b5-1 | 12,000 | $30.05 | $360,600 | 1,595 Direct | -88.27% | Disposed | -48.3% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 6, 2025 | FDMT | Stock Option (Right to Buy) | Common Stock (92,300) | $4.14 | March 5, 2035 | 92,300 | Acquired |
| Feb. 5, 2024 | FDMT | Stock Option (Right to Buy) | Common Stock (6,000) | $8.04 | Aug. 31, 2032 | 6,000 | Disposed |
| Feb. 5, 2024 | FDMT | Stock Option (Right to Buy) | Common Stock (6,000) | $15.78 | Jan. 31, 2032 | 6,000 | Disposed |
| Feb. 5, 2024 | FDMT | Stock Option (Right to Buy) | Common Stock (120,000) | $18.66 | Nov. 8, 2030 | 12,000 | Disposed |
| Dec. 11, 2023 | FDMT | Stock Option (Right to Buy) | Common Stock (250,000) | $14.42 | Dec. 10, 2033 | 250,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Feb. 7, 2024 | FDMT | Common Stock | 1,595 | Direct |
| April 5, 2023 | FDMT | Stock Options (Right to Buy)→ Common Stock (150,000) | 150,000 | Direct |
| April 5, 2023 | FDMT | Stock Options (Right to Buy)→ Common Stock (70,000) | 70,000 | Direct |
| April 5, 2023 | FDMT | Stock Options (Right to Buy)→ Common Stock (60,000) | 60,000 | Direct |
| April 5, 2023 | FDMT | Stock Options (Right to Buy)→ Common Stock (40,000) | 40,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
FDMT
M.D. Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $456,075 | — | — | $3,260,107 | $232,268 | — | $16,500 | $3,964,950 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.